Resistin-specific antibody and its use

Anti-resistin antibodies and related technologies inhibit resistin/CAP1 binding to address the challenges of human resistin-related diseases, offering therapeutic benefits in reducing inflammation, insulin resistance, and cancer progression.

JP2024542149AActive Publication Date: 2024-11-13SEOUL NAT UNIV HOSPITAL +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024526979
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-05
Filing Date
2022-11-04
Publication Date
2024-11-13
Estimated Expiration
2042-11-04

AI Technical Summary

Technical Problem

Current technologies lack effective therapeutic agents to inhibit the inflammatory and metabolic effects of human resistin, which is associated with diseases such as cancer, cardiometabolic disorders, and inflammatory diseases, due to unclear signal transduction pathways and species-specific differences in resistin function.

Method used

Development of anti-resistin antibodies and antigen-binding fragments that specifically inhibit resistin/CAP1 binding, along with nucleic acids encoding these antibodies, vector systems for expression, and immune cells equipped with chimeric antigen receptors to target resistin, thereby blocking its activity and reducing disease progression.

Benefits of technology

The anti-resistin antibodies demonstrate high therapeutic potential in inhibiting resistin activity, effectively reducing inflammation, insulin resistance, and metabolic disorders, as well as suppressing cancer cell migration and metastasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542149000001_ABST
    Figure 2024542149000001_ABST
Patent Text Reader

Abstract

The present invention relates to an antibody against resistin and uses thereof, more specifically to a resistin antibody or an antigen-binding fragment thereof that inhibits resistin activity by blocking resistin / CAP1 binding, a nucleic acid encoding the same, a vector containing the nucleic acid, a cell transformed with the vector, a method for producing the antibody or its antigen-binding fragment, an antibody-drug conjugate containing the antibody or its antigen-binding fragment, a bi- or multispecific antibody, a chimeric antigen receptor, an immune cell containing the same, and a composition containing the same for preventing or treating a disease treatable by inhibiting resistin activity. The novel antibody or antigen-binding fragment thereof that binds to resistin of the present invention can bind to resistin and inhibit its activity through blocking resistin / CAP1 binding, and is therefore useful for developing therapeutic agents for various resistin-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present application relates to an antibody against resistin and uses thereof, and more specifically, to an anti-resistin antibody or an antigen-binding fragment thereof that inhibits resistin activity by blocking resistin / CAP1 binding, a nucleic acid encoding the same, a vector containing the nucleic acid, a cell transformed with the vector, a method for producing the antibody or its antigen-binding fragment, an antibody-drug conjugate containing the antibody or its antigen-binding fragment, a bi- or multispecific antibody, a chimeric antigen receptor, an immune cell containing the same, and a composition for preventing or treating a disease that can be treated by inhibiting resistin activity, comprising the same. [Background technology]

[0002] Resistin is the first cytokine identified as a mediator of insulin resistance in obese mice. It belongs to the cysteine-rich protein family, also known as resistin-like molecules (RELMs), and is involved in the regulation of inflammatory processes. Murine resistin has also been implicated in the development of obesity-mediated insulin resistance and type 2 diabetes in rats (Li et al, Endocrine 35:243-251, 2009; Nakata et al, Biochem Biophys Res Commun. 353:1046-1051, 2007; Steppan et al, Nature 409:307-312, 2001).

[0003] In fact, the protein base sequences of rat and human resistin are only about 60% identical, and rodent resistin is primarily expressed and secreted in mature adipocytes, whereas human resistin is primarily secreted by peripheral blood mononuclear cells (PBMCs), such as leukocytes, and macrophages. Numerous studies have revealed that the roles of resistin differ between humans and rodents.

[0004] Human resistin has been reported to promote the influx of immune cells and induce the secretion of pro-inflammatory factors, and there is evidence that it induces inflammatory diseases and atherosclerosis in addition to promoting insulin resistance (Bokarewa et al, J Immunol. 174:5789-5795, 2005; Silswal et al, Biochem Biophys Res Commun. 334:1092-1101, 2005; Burnett et al, Atherosclerosis 182:241-248, 2005; Jung et al, Cardiovasc. Res 69:76-85, 2006; Reilly et al, Circulation 111:932-939, 2005). In addition, resistin, which is present in both rat and human atherosclerotic lesions, is known as an inflammatory marker of atherosclerosis in humans and is known to promote atherosclerosis by activating monocytes (Cho et al., J Am Coll Cardiol 57:99-109, 2011). Therefore, human resistin is thought to be a core element that stimulates monocytes leading to atherosclerosis.

[0005] The mechanism by which human resistin induces inflammation appears to be through activation of the NF-κB (nuclear factor kappa B) transcription factor; however, the signaling pathway underlying resistin's proinflammatory effects remains unclear, and the role of resistin in cancer remains unknown.

[0006] The present inventors were the first in the world to discover CAP1 (adenylyl cyclase associated protein 1), a receptor that directly interacts with human resistin (Lee S et al, Cell Metabolism, 19(3), 2014):484-97, 2014). Therefore, it has become possible to develop therapeutic agents for diseases caused by resistin using CAP1, a receptor that mediates the action of human resistin.

[0007] Therefore, the inventors have made extensive efforts to treat resistin-related diseases such as cancer by blocking resistin / CAP1 binding, and as a result, have produced a resistin-specific antibody that binds to resistin with high affinity, and have confirmed that such an anti-resistin antibody exhibits resistin / CAP1 binding inhibitory activity and high therapeutic effects against diseases that can be treated through inhibition of resistin activity, thereby completing the present invention.

[0008] The information provided in this Background section is intended solely to provide a deeper understanding of the background of the invention and may therefore not include information that constitutes prior art already known to a person of ordinary skill in the art to which the invention pertains. Summary of the Invention [Problem to be solved by the invention]

[0009] An object of the present invention is to provide a novel antibody or an antigen-binding fragment thereof against resistin. It is another object of the present invention to provide a nucleic acid encoding said antibody or antigen-binding fragment thereof.

[0010] Another object of the present invention is to provide a vector containing the nucleic acid, a cell transformed with the vector, and a method for producing the antibody or an antigen-binding fragment thereof using the same. Another object of the present invention is to provide an antibody-drug conjugate or a bi- or multispecific antibody comprising said antibody or antigen-binding fragment thereof. Another object of the present invention is to provide a chimeric antigen receptor comprising the antibody or an antigen-binding fragment thereof, and an immune cell comprising the chimeric antigen receptor.

[0011] Other objects of the present invention are to provide a pharmaceutical composition for preventing or treating a disease treatable by inhibition of resistin activity, comprising the antibody or antigen-binding fragment thereof, the antibody-drug conjugate, the bispecific or multispecific antibody, or the chimeric antigen receptor, and a method for preventing or treating a disease treatable by inhibition of resistin activity; use of the antibody or antigen-binding fragment thereof, antibody-drug conjugate, bispecific or multispecific antibody, or chimeric antigen receptor for preventing or treating a disease treatable by inhibition of resistin activity; and use of the antibody or antigen-binding fragment thereof, antibody-drug conjugate, bispecific or multispecific antibody, or chimeric antigen receptor for the manufacture of a medicament for preventing or treating a disease treatable by inhibition of resistin activity. [Means for solving the problem]

[0012] In order to achieve the above object, the present invention provides a heavy chain variable region comprising CDR1 comprising the amino acid sequence shown in SEQ ID NO:1, CDR2 comprising the amino acid sequence shown in SEQ ID NO:2, and CDR3 comprising the amino acid sequence shown in SEQ ID NO:3; and

[0013] The present invention provides an antibody or antigen-binding fragment thereof that specifically binds to resistin, comprising a light chain variable region including CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 to 11, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 to 19, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 to 27.

[0014] The present invention also provides a nucleic acid encoding the heavy chain variable region of the antibody or antigen-binding fragment thereof. The present invention also provides a nucleic acid encoding the light chain variable region of the antibody or antigen-binding fragment thereof. The present invention also provides a vector comprising the nucleic acid. The present invention also provides a cell transformed with the vector.

[0015] The present invention also provides a method for producing the antibody or antigen-binding fragment thereof, comprising the steps of: (a) culturing the cells; and (b) recovering the antibody or antigen-binding fragment thereof from the cultured cells.

[0016] The present invention also provides an antibody drug conjugate or a bi- or multispecific antibody comprising said antibody or antigen-binding fragment thereof. The present invention also provides a chimeric antigen receptor comprising the antibody or an antigen-binding fragment thereof, or an immune cell comprising the chimeric antigen receptor.

[0017] The present invention also provides a pharmaceutical composition for the prevention or treatment of a disease treatable by inhibiting the activity of resistin, comprising the antibody or antigen-binding fragment thereof, antibody-drug conjugate, bispecific or multispecific antibody, or chimeric antigen receptor.

[0018] The present invention also provides a method for preventing or treating a disease treatable by inhibition of resistin activity using the antibody or antigen-binding fragment thereof, antibody-drug conjugate, bispecific or multispecific antibody, or chimeric antigen receptor; use of the antibody or antigen-binding fragment thereof, antibody-drug conjugate, bispecific or multispecific antibody, or chimeric antigen receptor for the prevention or treatment of a disease treatable by inhibition of resistin activity; and use of the antibody or antigen-binding fragment thereof, antibody-drug conjugate, bispecific or multispecific antibody, or chimeric antigen receptor for the manufacture of a medicament for the prevention or treatment of a disease treatable by inhibition of resistin activity. [Brief description of the drawings]

[0019] [Figure 1] After the primary purification of the RETN-C-Fc antigen and the RETN-flag-His antigen, the purity was confirmed by analyzing them by SDS-PAGE. [Figure 2a] This is the polyphage ELISA result of the scFv phage pool using RETN-flag-His as the antigen in the first round of biopanning. [Figure 2b] This is the polyphage ELISA result of the scFv phage pool using RETN-C-Fc as the antigen in the first round of biopanning. [Figure 3a] This shows the results of an analysis of antigen-specific binding of monoclonal antibodies obtained in the first round of biopanning using RETN-flag-His as the antigen. [Figure 3b] This shows the results of an analysis of antigen-specific binding of monoclonal antibodies obtained in the first round of biopanning using RETN-C-Fc as the antigen. [Figure 4] These are the results of an analysis of the antigen receptor binding inhibitory ability of 16 proteins obtained in the first screening. [Diagram 5] The results show the antigen affinity of four clones analyzed using OCTET. [Figure 6] This is the analysis result of antigen-specific binding of 11 monoclonal antibodies obtained from the second screening. [Figure 7a] This shows the results of an analysis of antigen-specific binding of 10 monoclonal antibodies obtained from the first biopanning of the third screening. [Figure 7b] This shows the results of an analysis of antigen-specific binding of nine monoclonal antibodies obtained from the second biopanning of the third screening. [Figure 8] The figure shows five antibodies (11G01, 27A04, 32B05, 32E06, and 32G09) that have excellent antigen receptor binding inhibitory effects. [Figure 9a] This shows the results of ELISA analysis of the specific binding of 20 clones to the RETN-flag-His antigen. [Figure 9b] This shows the results of ELISA analysis of non-specific binding of 20 clones. [Figure 10] The results show the antigen affinity of six clones analyzed using OCTET. [Figure 11] FIG. 1 is a schematic diagram for the construction of a light chain shuffling library (LC shuffling library). [Figure 12] This shows the results of polyphage ELISA of the scFv phage pool obtained by biopanning with the light chain shuffling library. [Figure 13] This shows the change in productivity of 18 antibody-optimized clones relative to the parent antibody RETN-5A2 clone. [Figure 14] SDS-PAGE analysis of 18 antibody optimized clones. [Figure 15a] The binding affinity of 18 optimized antibodies to the RETN-flag-His antigen was analyzed by ELISA. [Figure 15b] The non-specific binding of 18 optimized antibodies was analyzed by ELISA. [Figure 15c] The binding ability of 13 optimized antibodies to the intact form resistin antigen was analyzed by ELISA. [Figure 16] The interspecies cross-binding activity of eight optimized antibodies against mouse resistin antigen was examined by ELISA. [Figure 17a] FIG. 1 is a schematic diagram of an antigen receptor competitive enzyme immunoassay. [Figure 17b] The ability of 18 optimized antibodies to inhibit antigen receptor binding was evaluated using an antigen receptor competitive enzyme immunoassay. [Figure 18] The ability to inhibit antigen receptor binding was analyzed by pull-down assay. [Figure 19] The results show the antigen affinity of seven optimized antibody clones analyzed using OCTET. [Figure 20]After treating breast cancer cells with resistin, the activation of NF-κB by resistin was measured by phosphorylation of p65. [Figure 21] The 5A2 antibody and hIgG control were administered to mice, and the pharmacokinetics was measured. [Figure 22] FIG. 1 shows the inhibition of breast cancer cell migration in vitro by the 5A2 antibody. [Diagram 23] FIG. 1 shows the in vivo inhibition of metastasis of breast cancer cells by the 5A2 antibody. [Figure 24] FIG. 1 is a schematic diagram of an experiment in a mouse NASH model to confirm the effect of 5A2 antibody. [Diagram 25] This shows the results of H&E analysis confirming that administration of 5A2 antibody to mice suppressed fatty liver. [Figure 26] This shows the results of oil-red-o analysis confirming that administration of 5A2 antibody to mice suppressed fatty liver. [Figure 27] 1 is a graph showing insulin sensitivity when 5A2 antibody was administered to mice. [Figure 28] 1 shows a graph confirming the reduction in fasting blood glucose levels when 5A2 antibody was administered to mice. [Figure 29] 1 is a graph confirming the reduction in LDL cholesterol when 5A2 antibody was administered to mice. [Diagram 30] 1 shows a graph confirming the reduction in hepatic triglycerides when 5A2 antibody was administered to mice. [Diagram 31] FIG. 1 is a schematic diagram of an experiment in a mouse IBD model to confirm the effect of the RETN-5A2_LS_2F11 antibody. [Diagram 32] FIG. 1 shows the effect of suppressing weight loss in mice by administration of the RETN-5A2_LS_2F11 antibody in an IBD mouse model. [Diagram 33] FIG. 1 shows the inhibitory effect of administration of the RETN-5A2_LS_2F11 antibody on an increase in disease activity score in an IBD mouse model. [Diagram 34]FIG. 1 shows the intestinal long-term protective effect of administration of the RETN-5A2_LS_2F11 antibody in an IBD mouse model. [Diagram 35] This shows the results of measuring the histological activity score when the RETN-5A2_LS_2F11 antibody was administered to an IBD mouse model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein is one that is well known and commonly used in the art.

[0021] The inventors of the present application used a biopanning method to screen for novel resistin human antibodies that have high affinity for human resistin and excellent ability to inhibit binding between resistin antigen receptors, and confirmed that the screened resistin human antibodies exhibit anti-cancer effects that suppress the migration and metastasis of cancer cells.

[0022] Thus, in one aspect, the present invention provides a heavy chain variable region comprising a CDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a CDR2 comprising the amino acid sequence shown in SEQ ID NO:2, and a CDR3 comprising the amino acid sequence shown in SEQ ID NO:3; and The present invention relates to an antibody or antigen-binding fragment thereof that specifically binds to resistin, comprising a light chain variable region including CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 to 11, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 to 19, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 to 27.

[0023] In the present invention, the light chain variable region comprises: a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:4, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:12, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:20; a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:13, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:21; a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:6, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:14, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:22; a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:7, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:23; a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:8, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:16, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:24; a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:9, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:17, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:25; a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:10, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:18, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:26; or It may be characterized as a light chain variable region comprising CDR1 having the amino acid sequence shown in SEQ ID NO:11, CDR2 having the amino acid sequence shown in SEQ ID NO:19, and CDR3 having the amino acid sequence shown in SEQ ID NO:27.

[0024] Furthermore, in the present invention, the heavy chain variable region preferably comprises the amino acid sequence shown in SEQ ID NO: 28, and the light chain variable region preferably comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 34, 36, 38, 40, 42, 44, and 46. More preferably, the antibody or antigen-binding fragment thereof of the present invention comprises, but is not limited to, a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 28; and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 34, 36, 38, 40, 42, 44, and 46.

[0025] The heavy chain variable region CDR sequences (SEQ ID NOs: 1, 2, and 3) of the antibodies of the present invention that specifically bind to resistin are shown in Table 1 below.

[0026] The light chain variable region CDR sequences (SEQ ID NOs: 4 to 27) of the antibodies of the present invention that specifically bind to resistin are shown in the following Table 2. SEQ ID NOs: 11, 19 and 27 show the sequences of the light chain variable region CDR1, 2 and 3 of the resistin 5A2 parent antibody.

[0027] The amino acid sequence (SEQ ID NO: 28) of the heavy chain variable region and the amino acid sequence (SEQ ID NO: 29) of the heavy chain constant region of the antibody of the present invention that specifically binds to resistin are shown in Table 3 below.

[0028] The amino acid sequences of the light chain variable regions (SEQ ID NOs: 32, 34, 36, 38, 40, 42, 44, and 46) and the light chain constant regions (SEQ ID NOs: 33, 35, 37, 39, 41, 43, 45, and 47) of the antibodies of the present invention that specifically bind to resistin are shown in Table 5. SEQ ID NO: 46 is the amino acid sequence of the light chain variable region of the resistin 5A2 parent antibody, and SEQ ID NO: 47 shows the amino acid sequence of the light chain constant region of the resistin 5A2 parent antibody.

[0029] [Table 1]

[0030] [Table 2]

[0031] [Table 3]

[0032] [Table 4] TIFF2024542149000006.tif72170

[0033] [Table 5] TIFF2024542149000008.tif211170

[0034] [Table 6] TIFF2024542149000010.tif244170TIFF2024542149000011.tif244170TIFF2024542149000012.tif243170TIFF2024542149000013.tif97170

[0035] The term "antibody" as used herein refers to an anti-resistin antibody that specifically binds to resistin, particularly human resistin. The scope of the present invention includes intact antibody forms that specifically bind to resistin as well as antigen-binding fragments of said antibody molecules.

[0036] Intact antibodies have two full-length light chains and two full-length heavy chains, each linked to a heavy chain by disulfide bonds. The heavy chain constant regions are of gamma (γ), mu (μ), alpha (α), delta (δ) and epsilon (ε) types, with subclasses gamma 1 (γ1), gamma 2 (γ2), gamma 3 (γ3), gamma 4 (γ4), alpha 1 (α1) and alpha 2 (α2). The light chain constant regions are of kappa (κ) and lambda (λ) types.

[0037] The antigen-binding fragment of an antibody or antibody fragment means a fragment having an antigen-binding function, and includes Fab, F(ab'), F(ab')2, Fv, and the like. Among antibody fragments, Fab has a structure having a light chain and a heavy chain variable region, a light chain constant region, and the first constant region (CH1) of the heavy chain, and has one antigen-binding site. Fab' differs from Fab in that it has a hinge region containing one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. F(ab')2 antibodies are generated by disulfide bond formation between cysteine ​​residues in the hinge region of Fab'. Fv is the smallest antibody fragment having only a heavy chain variable region and a light chain variable region, and recombinant techniques for generating Fv fragments are disclosed in PCT International Publication Nos. WO88 / 10649, WO88 / 106630, WO88 / 07085, WO88 / 07086, and WO88 / 09344. In two-chain Fv, the heavy chain variable region and the light chain variable region are linked by a non-covalent bond, while in single-chain Fv (scFv), the heavy chain variable region and the light chain variable region are generally linked by a covalent bond via a peptide linker or directly at the C-terminus, and can form a dimer structure like two-chain Fv. Such antibody fragments can be obtained using proteolytic enzymes (for example, Fab can be obtained by restrictive cleavage of the whole antibody with papain, and F(ab')2 fragments can be obtained by cleavage with pepsin), or can be produced through gene recombination technology.

[0038] In one embodiment, the antibody according to the invention is in Fv format (e.g., scFv) or in whole antibody format. The heavy chain constant region may be selected from any of the isotypes: gamma (γ), mu (μ), alpha (α), delta (δ) or epsilon (ε). For example, the constant region is gamma 1 (IgG1), gamma 3 (IgG3) or gamma 4 (IgG4). The light chain constant region may be of the kappa or lambda type.

[0039] The term "heavy chain" as used herein refers to both a full-length heavy chain and fragments thereof that includes a variable region domain VH and three constant region domains CH1, CH2 and CH3 that contain an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen. Additionally, the term "light chain" as used herein refers to both a full-length light chain and fragments thereof that includes a variable region domain VL and a constant region domain CL that contain an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen.

[0040] Antibodies of the present invention include, but are not limited to, monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single-chain Fvs (scFV), single-chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFV) and anti-idiotypic (anti-Id) antibodies, or epitope-binding fragments of the above antibodies.

[0041] The monoclonal antibody refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies that make up the population are identical except for naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific and directed against a single antigen site. In contrast to conventional (polyclonal) antibody preparations that usually contain different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.

[0042] For example, the monoclonal antibodies useful in the present invention may be prepared by the hybridoma method or using recombinant DNA methods from bacterial, eukaryotic or plant cells (see U.S. Patent No. 4,816,567), or the monoclonal antibodies may be isolated from phage antibody libraries.

[0043] "Epitope" refers to a determinant on a protein to which an antibody can specifically bind. Epitopes are usually composed of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and generally have specific three-dimensional structural features as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

[0044] The "humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In most cases, humanized antibodies are human immunoglobulins (receptor antibodies) in which residues from a hypervariable region of a receptor have been replaced with residues from a hypervariable region of a non-human species (donor antibody), such as mouse, rat, rabbit, or non-human primate, that has the desired specificity, affinity, and capacity.

[0045] The "human antibody" refers to a molecule derived from human immunoglobulin, and all of the amino acid sequences constituting the antibody, including the complementarity determining regions and structural regions, are entirely composed of human immunoglobulin.

[0046] These include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical to or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remaining chain(s) is identical to or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.

[0047] As used herein, "antibody variable domain" refers to the light and heavy chain portions of an antibody molecule that contain the amino acid sequences of the complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) and framework regions (FRs). VH refers to the variable domain of the heavy chain. VL refers to the variable domain of the light chain.

[0048] "Complementarity determining region" (CDR; i.e., CDR1, CDR2, and CDR3) refers to the amino acid residues of an antibody variable domain that are necessary for antigen binding. Each variable domain typically has three CDR regions identified as CDR1, CDR2, and CDR3.

[0049] An "Fv" fragment is an antibody fragment that contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in substantially tight covalent association, e.g., as an scFv.

[0050] The "Fab" fragment contains the variable and constant domains of the light chain and the variable and first constant domain (CH1) of the heavy chain. F(ab')2 antibody fragments usually contain a pair of Fab fragments covalently linked near their carboxy termini by hinge cysteines between them.

[0051] "Single-chain Fv" or "scFv" antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. The Fv polypeptide may further comprise a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding.

[0052] The antibody according to the present invention has an increased affinity for an antigen. The term "affinity" refers to the ability to specifically recognize and bind to a specific site of an antigen, and high affinity, along with the specificity of an antibody to an antigen, are important factors in an immune response. Affinity can be determined using any of a variety of assays known in the art, such as radioimmunoassay (RIA) and ELISA, and can be expressed in a variety of quantitative values. The affinity of an antibody to an antigen can generally be expressed by the dissociation constant (Kd) of a particular antibody-antigen interaction. A lower Kd value means a higher affinity of the antibody to the antigen.

[0053] The antibody or antibody fragment of the present invention may include not only the sequence of the anti-resistin antibody of the present invention described herein, but also its biological equivalents, so long as it can specifically recognize resistin. For example, additional modifications may be made to the amino acid sequence of the antibody to further improve the binding affinity and / or other biological properties of the antibody. Such modifications include, for example, deletion, insertion and / or substitution of residues in the amino acid sequence of the antibody. Such amino acid modifications are made based on the relative similarity of the amino acid side chain substitutes, such as hydrophobicity, hydrophilicity, charge, size, etc. Analysis of the size, shape and type of amino acid side chain substitutes shows that arginine, lysine and histidine are all positively charged residues; alanine, glycine and serine have similar sizes; and phenylalanine, tryptophan and tyrosine have similar shapes. Therefore, based on these considerations, it can be said that arginine, lysine, histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine are biologically functionally equivalent.

[0054] Considering the above-mentioned biologically equivalent mutations, the antibody of the present invention or the nucleic acid molecule encoding it is also understood to include sequences that show substantial identity with the sequences described in SEQ ID NO. The substantial identity means a sequence that shows at least 90% homology, most preferably at least 95% homology, 96% or more, 97% or more, 98% or more, or 99% or more homology when the above-mentioned sequence of the present invention is aligned with any other sequence as closely as possible and the aligned sequences are analyzed using an algorithm commonly used in the art. Alignment methods for sequence comparison are known in the art. The NCBI Basic Local Alignment Search Tool (BLAST) can be accessed from NBCI, etc., and can be used in conjunction with sequence analysis programs such as blastp, blasm, blastx, tblastn, and tblastx on the Internet. BLSAT can be accessed at https: / / blast.ncbi.nlm.nih.gov / Blast.cgi. Methods for sequence homology comparison using this program can be found at https: / / blast.ncbi.nlm.nih.gov / doc / blast-help.

[0055] On this basis, the antibodies or antigen-binding fragments thereof of the present invention may have 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homology compared to the sequences described herein or to the entirety. Such homology may be determined by sequence comparison and / or alignment by methods known to those of skill in the art. For example, percent sequence homology of the nucleic acids or proteins of the present invention may be determined using sequence comparison algorithms (i.e., BLAST or BLAST 2.0), manual alignment, and visual inspection.

[0056] In another aspect, the present invention relates to a nucleic acid encoding the heavy chain variable region of the antibody or antigen-binding fragment thereof.

[0057] In the present invention, the nucleic acid is preferably a nucleic acid encoding a heavy chain variable region of an antibody that specifically binds to resistin, comprising the amino acid sequence shown in SEQ ID NO: 28, and more preferably, may be characterized as having the base sequence shown in SEQ ID NO: 30, the sequence of which is shown in Table 4 above.

[0058] In another aspect, the present invention relates to a nucleic acid encoding the light chain variable region of the antibody or antigen-binding fragment thereof.

[0059] In the present invention, the nucleic acid is preferably a nucleic acid encoding a light chain variable region of an antibody that specifically binds to resistin, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 34, 36, 38, 40, 42, 44, and 46, and more preferably a base sequence selected from the group consisting of SEQ ID NOs: 48, 50, 52, 54, 56, 58, 60, and 62, and the sequence is shown in Table 6.

[0060] The term "nucleic acid" encompasses DNA (gDNA and cDNA) and RNA molecules, and nucleotides, which are the basic building blocks of nucleic acids, include not only natural nucleotides but also analogues in which the sugar or base moiety has been modified. The sequences of the nucleic acids encoding the heavy and light chain variable regions of the present invention may be modified. The modifications include addition, deletion, or non-conservative or conservative substitution of nucleotides.

[0061] DNA encoding the antibody is readily isolated or synthesized using conventional processes (e.g., by using oligonucleotide probes capable of specifically binding to DNA encoding the heavy and light chains of the antibody). Many vectors are available. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

[0062] The antibody or antigen-binding fragment thereof may be produced recombinantly by isolating a nucleic acid encoding an antibody or antigen-binding fragment thereof of the invention, isolating the nucleic acid and inserting it into a replicable vector for further cloning (amplification of the DNA) or for further expression.

[0063] Based on this, in another aspect, the present invention relates to a vector comprising the nucleic acid. The term "vector" as used herein includes, as a means for expressing a gene of interest in a host cell, plasmid vectors, cosmid vectors, bacteriophage vectors, adenovirus vectors, retrovirus vectors, adeno-associated virus vectors, and other viral vectors, etc. In the vector, the nucleic acid encoding the antibody is operably linked to a promoter.

[0064] "Operably linked" refers to a functional connection between a nucleic acid expression control sequence (e.g., a promoter, a signal sequence, or an array of transcriptional regulator binding sites) and another nucleic acid sequence, whereby the control sequence controls the transcription and / or detoxification of the other nucleic acid sequence.

[0065] When a prokaryotic cell is used as the host, it generally contains a strong promoter capable of driving transcription (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, T7 promoter, etc.), a ribosome binding site for initiating detoxification, and a transcription / detoxification termination sequence. Furthermore, for example, when a eukaryotic cell is used as the host, a promoter derived from the genome of a mammalian cell (e.g., metallothionine promoter, β-actin promoter, human hemoglobin promoter, and human muscle creatine promoter) or a promoter derived from a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, HSV tk promoter, mouse mammary tumor virus (MMTV) promoter, HIV LTR promoter, Moloney virus promoter, Epstein-Barr virus (EBV) promoter, and Rous sarcoma virus (RSV) promoter) may be used, and generally has a polyadenylation sequence as a transcription termination sequence.

[0066] In some cases, the vector may be fused to other sequences to facilitate purification of the antibody expressed therefrom, such as glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and 6x His (hexahistidine; Quiagen, USA).

[0067] The vectors contain as selection markers antibiotic resistance genes commonly used in the art, such as ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline resistance genes.

[0068] Meanwhile, the vector expressing the resistin-specific antibody or its antigen-binding fragment can be either a vector system in which the nucleic acid encoding the heavy chain variable region and the nucleic acid encoding the light chain variable region are simultaneously expressed in one vector, or a system in which the light chain and the heavy chain are expressed in separate vectors. In the latter case, the two vectors can be introduced into a host cell through co-transformation and targeted transformation. Also, cells transformed with a vector containing a light chain (or heavy chain) can be screened, and the screened cells can be transformed again with a vector containing a heavy chain (or light chain) to finally screen for cells expressing both the light chain and the heavy chain.

[0069] Although not limited thereto, a vector system in which a nucleic acid encoding a heavy chain variable region and a nucleic acid encoding a light chain variable region of a resistin-specific antibody or its antigen-binding fragment are simultaneously expressed in one vector is preferred.

[0070] From another aspect, the present invention relates to a cell transformed with the above vector. In the present invention, the cell may be characterized in that it is selected from the group consisting of animal cells, plant cells, yeast, E. coli and insect cells, but is not limited thereto. The cells used to produce the antibodies of the present invention may be, but are not limited to, prokaryotic, yeast, or higher eukaryotic cells.

[0071] Prokaryotic host cells such as strains of the genus Bacillus, such as Escherichia coli, Bacillus subtilis and Bacillus thuringiensis, Streptomyces, Pseudomonas (e.g., Pseudomonas putida), Proteus mirabilis, and Staphylococcus (e.g., Staphylococcus carnosus) may be used.

[0072] However, of most interest to animal cells, examples of useful host cell lines may be, but are not limited to, COS-7, BHK, CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC5, FS4, 3T3, RIN, A549, PC12, K562, PER.C6, SP2 / 0, NS-0, U20S, or HT1080.

[0073] In another aspect, the present invention relates to a method for producing the antibody or antigen-binding fragment thereof, comprising the steps of: (a) culturing the cells; and (b) recovering the antibody or antigen-binding fragment thereof from the cultured cells.

[0074] The cells may be cultured in various media. The culture medium may be any commercially available medium without limitation. It may contain any other necessary supplements known to those skilled in the art at appropriate concentrations. The culture conditions, such as temperature, pH, etc., are already used with the host cell selected for expression, and it is obvious to those skilled in the art.

[0075] The antibody or antigen-binding fragment thereof may be recovered by, for example, removing impurities by centrifugation or ultrafiltration, and the resulting product may be purified, for example, by affinity chromatography. Additional purification techniques, such as anion or cation exchange chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography, etc., may also be used.

[0076] From another aspect, the present invention relates to an antibody-drug conjugate (ADC) in which a drug is bound to an antibody or an antigen-binding fragment thereof that specifically binds to resistin.

[0077] In antibody-drug conjugates, the drug must be stably bound to the antibody until it is delivered to the target cell. The drug delivered to the target, for example, an anticancer drug, must be released from the antibody to induce the death of the target cell. For this purpose, the drug must be stably bound to the antibody and at the same time have sufficient cytotoxicity to induce the death of the target cell when released from the target cell.

[0078] In the present invention, the antibody or antigen-binding fragment thereof and the cytotoxic substance including a drug such as an anticancer drug may be bonded to each other (e.g., by a covalent bond, a peptide bond, etc.) and used in the form of a conjugate or a fusion protein (when the cytotoxic substance and / or the marker substance is a protein). The cytotoxic substance may be any substance that is toxic to cancer cells, particularly solid cancer cells, and may be one or more selected from the group consisting of a radioisotope, a cytotoxic small molecule, a cytotoxic protein, an anticancer drug, etc., but is not limited thereto. The cytotoxic protein may be one or more selected from the group consisting of ricin, saporin, gelonin, momordin, debouganin, diphtheria toxin, pseudomonas toxin, etc., but is not limited thereto. The radioisotope may be one or more selected from the group consisting of 131I, 188Rh, 90Y, etc., but is not limited thereto. The cytotoxic compound may be one or more selected from the group consisting of duocarmycin, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine (DM1), PBD (pyrrolobenzodiazepine) dimer, and the like, but is not limited thereto.

[0079] In the present invention, the antibody-drug conjugate may be prepared by a technique well known in the technical field to which the present invention pertains. In the present invention, the antibody-drug conjugate may be characterized in that the antibody or antigen-binding fragment thereof is bound to a drug via a linker. In the present invention, the linker may be characterized as being a cleavable linker or a non-cleavable linker.

[0080] The linker is a moiety that connects the anti-resistin antibody and the drug, for example, the linker is in a form that is cleavable under intracellular conditions, i.e., allows the drug to be released from the antibody by cleavage of the linker in the intracellular environment.

[0081] The linker may be a peptide linker that may be cleaved by a cleavage agent present in the intracellular environment, for example, in a lysosome or endosome, or may be cleaved by an intracellular peptidase or protease enzyme, for example, a lysosomal or endosomal protease. In general, the peptide linker has a length of at least two or more amino acids. The cleavage agent may include cathepsin B and cathepsin D, plasmin, which hydrolyzes the peptide and allows the drug to be released into the target cell. The peptide linker may be cleaved by the thiol-dependent protease cathepsin B, which is highly expressed in cancer tissues, for example, a Phe-Leu or Gly-Phe-Leu-Gly linker may be used. The peptide linker may also be, for example, a Val-Cit linker or a Phe-Lys linker that may be cleaved by an intracellular protease.

[0082] In the present invention, the cleavable linker may be pH sensitive and sensitive to hydrolysis at a certain pH value.Generally, pH sensitive linker indicates that it can be hydrolyzed under acidic conditions.For example, the acid labile linker that can be hydrolyzed in lysosomes may be, for example, hydrazone, semicarbazone, thiosemicarbazone, cis-aconitic amide, orthoester, acetal, ketal, etc.

[0083] The linker may be cleaved under reducing conditions, for example, a disulfide linker. SATA (N-succinimidyl-S-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio)butyrate) and SMPT (N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio)toluene) may be used to form various disulfide bonds.

[0084] In the present invention, the drug and / or drug linker may be randomly linked via lysines of the antibody or via cysteines exposed when the disulfide bond chain is reduced. In some cases, the linker drug may be linked via cysteines present in a genetically engineered tag, e.g., a peptide or protein. The genetically engineered tag, e.g., a peptide or protein, may include an amino acid motif that can be recognized by, e.g., an isoprenoid transferase. The peptide or protein may have a deletion at the carboxy terminus of the peptide or protein or a covalent attachment of a spacer unit to the carboxy (C) terminus of the peptide or protein. The peptide or protein may be directly covalently linked to the amino acid motif or may be covalently linked to the spacer unit to link the amino acid motif. The amino acid spacer unit is composed of 1 to 20 amino acids, among which a glycine unit is preferred.

[0085] The linker may include a β-glucuronide linker that is recognized and hydrolyzed by β-glucuronidase, which is abundantly present in lysosomes or overexpressed in some tumor cells. Unlike peptide linkers, it has a high hydrophilicity, and therefore has the advantage of increasing the solubility of the antibody-drug conjugate when conjugated with a highly hydrophobic drug.

[0086] In this regard, the present invention may use a β-glucuronide linker disclosed in Korean Patent Publication No. 2015-0137015, for example, a β-glucuronide linker containing a self-immolative group.

[0087] Alternatively, the linker may be, for example, a non-cleavable linker, which releases the drug in just one step of antibody hydrolysis, for example, to generate an amino acid linker-drug conjugate. This type of linker may be a thioether group or a maleimidocaproyl group, and can maintain stability in the blood.

[0088] In the present invention, the drug may be a chemotherapeutic agent, a toxin, a microRNA (miRNA), an siRNA, an shRNA, or a radioisotope. The drug may be bound to an antibody as a pharmaceutical agent that exhibits a pharmacological effect.

[0089] The chemotherapeutic agent may be a cytotoxic agent or an immunosuppressant. Specifically, it may include chemotherapeutic agents that can function as microtubulin inhibitors, mitotic inhibitors, topoisomerase inhibitors, or DNA intercalators. It may also include immunomodulatory compounds, anticancer agents, antiviral agents, antibacterial agents, antifungal agents, antiparasitic agents, or combinations thereof.

[0090] The drugs include, for example, maytansinoids, orlistatin, aminopterin, actinomycin, bleomycin, thalidomide, camptothecin, N8-acetylspermidine, 1-(2-chloroethyl)-1,2-dimethylsulfonylhydrazide, esperamicin, etoposide, 6-mercaptopurine, dolostatin, trichothecenes, calicheamicins, taxol, taxanes, paclitaxel, docetaxel, methotrexate, vincristine, vinblastine, doxorubicin, melphalan, chlorambucil, duocarmycin, L-asparaginase, ginase, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosourea, cisplatin, carboplatin, mitomycin (mitomycin A, mitomycin C), dacarbazine, procarbazine, topotecan, nitrogen mustardmustard, cytoxan, 5-fluorouracil, CNU (bischloroethylnitrosourea), irinotecan, camptothecin, idarubicin, daunorubicin, dactinomycin, plicamycin, asparaginase, vinorelbine, chlorambucil ( chlorambucil, melphalan, carmustine, lomustine, busulfan, treosulfan, decarbazine, teniposide, topotecan, 9-aminocamptothecin, crisnatol, trimetrexate, mycophenolic acid acid, tiazofurin, ribavirin, EICAR (5-ethynyl-1-beta-dribofuranosylimidazole-4-carboxamide), hydroxyurea, deferoxamine, floxuridine, doxifluridine, raltitrexed, cytarabine (ara C), cytosine arabinoside, fludarabine, tamoxifen, raloxifene, megestrol, goserelin, leuprolide acetateacetate), flutamide, bicalutamide, EB1089, CB1093, KH1060, verteporfin, phthalocyanine, photosensitizer Pe4, demethoxy-hypocrellin A, interferon-α, interferon-γ, tumor necrosis factor, gemcitabine, velcade, Revlimid, lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, actinomycin D D), dactinomycin, bleomycin A2, bleomycin B2, peplomycin, epirubicin, pirarubicin, zorubicin, mitoxantrone, verapamil, and thapsigargin, nucleases, and toxins derived from bacteria, animals, and plants, but are not limited thereto.

[0091] In the present invention, the drug may contain one or more nucleophilic groups selected from the group consisting of amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups that can react to form covalent bonds with electrophilic groups on the linker and linker reagent.

[0092] From another aspect, the present invention relates to a bisspecific or multi-specific antibody comprising the antibody or antigen-binding fragment thereof that specifically binds to resistin.

[0093] A bispecific antibody refers to an antibody that has binding or antagonistic capabilities to more than one target, and refers to a combination of antibodies that have binding or antagonistic capabilities to two different targets, or an antibody that has binding capabilities for one target and is bound to a substance that has antagonistic capabilities to another target.

[0094] A multispecific antibody refers to an antibody that has binding specificities for at least three or more different antigens. A multispecific antibody may include trispecific or more antibodies, such as trispecific antibodies, tetraspecific antibodies, or antibodies that target more than two targets.

[0095] Methods for producing bispecific or multispecific antibodies are widely known. Traditionally, recombinant production of bispecific antibodies is based on the co-expression of two or more immunoglobulin heavy / light chain pairs under conditions where the two or more heavy chains have different specificities.

[0096] The antigen to which the antibody other than the anti-resistin antibody contained in the bispecific or multispecific antibody binds is preferably a cancer-associated antigen or an immune checkpoint protein antigen, such as HGF, EGFR, EGFRvIII, Her2, Her3, IGF-1R, VEGF, VEGFR-1, VEGFR-2, VEGFR-3, Ang2, Dll4, NRP1, FGFR, FGFR2, FGFR3, c-Kit, MUC1, MUC16, CD20, CD22, CD27, CD30, CD33, CD40, CD52, CD70, CD79, DDL3, Folate R1, or Nectin. 4, Trop2, gpNMB, Axl, BCMA, PD-1, PD-L1, PD-L2, CTLA4, BTLA, 4-1BB, ICOS, GITR, OX40, VISTA, TIM-3, LAG-3, KIR, B7.1, B7.2, B7-H2, B7-H3, B7-H4, B7-H6, B7-H7, EphA2, EphA4, EphB2, E-selectin, EpCam, CEA, PSMA, PSA, c-MET, etc., and immune effector cell-associated antigens may be selected from, but are not limited to, TCR / CD3, CD16 (FcγRIIIa), CD44, CD56, CD69, CD64 (FcγRI), CD89, CD11b / CD18 (CR3), etc.

[0097] From another aspect, the present invention relates to a chimeric antigen receptor (CAR) comprising an antibody or an antigen-binding fragment thereof that specifically binds to resistin.

[0098] The CAR may comprise an antigen binding domain, a transmembrane domain and an intracellular signaling domain, and the antigen binding domain may be linked to the transmembrane domain by a linker. The extracellular domain comprising the antigen binding domain may comprise a signal peptide.

[0099] From another aspect, the present invention relates to an immune cell containing the chimeric antigen receptor. The immune cells may be characterized as comprising cells genetically modified to express the chimeric antigen receptor, preferably T cells or NK cells.

[0100] From another aspect, the present invention relates to a pharmaceutical composition for preventing or treating a disease that can be treated by inhibiting resistin activity, comprising the antibody or antigen-binding fragment thereof, the antibody-drug conjugate, the bispecific or multispecific antibody, or the chimeric antigen receptor.

[0101] In the present invention, the activity of resistin may be characterized in that the resistin / CAP1 binding is blocked by a resistin antibody, thereby inhibiting the activity. In the present invention, the disease treatable by inhibiting the activity of resistin is preferably, but is not limited to, cancer, cardiometabolic disease, autoimmune disease, or inflammatory disease.

[0102] The present invention may be, for example, a pharmaceutical composition for preventing or treating cancer, cardiometabolic disease, autoimmune disease or inflammatory disease, comprising (a) a pharma- ceutical effective amount of an antibody or antigen-binding fragment thereof that specifically binds to resistin according to the present invention; and (b) a pharma-ceutical acceptable carrier. The present invention also relates to a method for preventing or treating cancer, cardiometabolic disease, autoimmune disease or inflammatory disease, comprising the step of administering to a patient an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to resistin according to the present invention.

[0103] Therefore, from another aspect, the present invention relates to a method for preventing or treating a disease that can be treated by inhibiting resistin activity, the method comprising the step of administering to a subject a composition comprising the antibody or antigen-binding fragment thereof, the antibody-drug conjugate, the bispecific or multispecific antibody, or the chimeric antigen receptor.

[0104] From another aspect, the present invention relates to use of the antibody or antigen-binding fragment thereof, the antibody-drug conjugate, the bispecific or multispecific antibody, or the chimeric antigen receptor, or a composition containing them, for the prevention or treatment of a disease treatable by inhibition of resistin activity.

[0105] From another aspect, the present invention relates to use of the antibody or antigen-binding fragment thereof, the antibody-drug conjugate, the bispecific or multispecific antibody, or the chimeric antigen receptor, or a composition containing them, for the manufacture of a medicament for the prevention or treatment of a disease that can be treated by inhibiting resistin activity.

[0106] The above-mentioned compositions, methods, applications and uses use the above-mentioned anti-resistin antibody or antigen-binding fragment thereof of the present invention as an active ingredient, and therefore overlapping content will not be described here.

[0107] "Prevention" means any action of suppressing or slowing the progression of a disease treatable by inhibition of resistin activity by administering a composition according to the present invention, and "treatment" means suppressing the progression, alleviating or eliminating a disease treatable by inhibition of resistin activity.

[0108] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals in which a population of cells is characterized by unregulated cell growth.

[0109] "Tumor" refers to any mass of tissue caused by excessive cell growth or proliferation, which may be benign (non-cancerous) or malignant (cancerous), including pre-cancerous lesions.

[0110] "Cancer cells," "tumor cells," and grammatical equivalents refer to the total population of cells derived from a tumor or precancerous lesion, including both non-tumorigenic cells, which comprise the bulk of the tumor cell population, and tumorigenic stem cells (cancer stem cells).

[0111] The "cancer" in the present invention includes any type of cancer in which resistin is expressed, and is preferably selected from the group consisting of breast cancer, metastatic cancer, uterine cancer, ovarian cancer, prostate cancer, melanoma, lung cancer, liver cancer, glioma, colorectal cancer, head and neck cancer, bladder cancer, renal cell carcinoma, gastric cancer, pancreatic cancer, and recurrent cancer, but is not limited thereto.

[0112] In particular, the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the same of the present invention may be characterized by inhibiting cancer metastasis. In the present invention, the "cardiometabolic disease, autoimmune disease, or inflammatory disease" includes, without limitation, any disease in which resistin is expressed.

[0113] In the present invention, the cardiometabolic disease is preferably selected from the group consisting of obesity, hyperlipidemia, hypertension, arteriosclerosis, hyperinsulinemia, insulin-resistant diabetes, type 2 diabetes, liver disease, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), but is not limited thereto.

[0114] In the present invention, the autoimmune disease is preferably selected from the group consisting of chronic heart disease, rheumatoid arthritis, systemic erythematous cyst, digestive system diabetes, atopic dermatitis, autoimmune encephalomyelitis, asthma, and Crohn's disease, but is not limited thereto.

[0115] In the present invention, the inflammatory disease is preferably selected from the group consisting of inflammatory skin diseases including asthma, eczema, psoriasis, acne, allergy, rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, atopic rhinitis, allergic dermatitis, chronic sinusitis or seborrheic dermatitis; inflammatory bowel disease (IBD) including Crohn's disease or ulcerative colitis, ankylosing spondylitis, sepsis, septic shock, vasculitis and bursitis, and acute or chronic inflammatory diseases including, but not limited to, these.

[0116] The pharmaceutical composition of the present invention may contain an antibody or a fragment thereof specific to resistin, and the above components may further include a pharma- ceutically acceptable carrier for administering the pharmaceutical composition of the present invention.

[0117] In the present invention, the term "pharmaceutical acceptable carrier" refers to a carrier or diluent that does not stimulate the living body and does not inhibit the biological activity and properties of the administered compound. In the composition formulated into a liquid solution, the pharmaceutical acceptable carrier is one that is sterile and suitable for the living body, and may be used by mixing one or more of physiological saline, sterile water, buffered physiological saline, albumin injection, dextrose solution, maltodextrin solution, glycerol, and other components thereof, and other common additives such as antioxidants, buffers, bacteriostatic agents, etc. may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be further added to formulate into injection preparations such as aqueous solutions, suspensions, and emulsions, as well as pills, capsules, granules, or tablets.

[0118] The pharmaceutical composition of the present invention may be in various oral or parenteral dosage forms. When formulated, it is prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, or surfactant that is commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing one or more compounds with at least one or more excipients, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, liquids, emulsions, syrups, etc., and may contain various excipients such as wetting agents, sweeteners, flavorings, preservatives, etc. in addition to water and liquid paraffin, which are commonly used simple diluents. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized agents, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. may be used. As bases for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, etc. may be used.

[0119] In another aspect, the present invention provides a method for inhibiting the growth, migration or metastasis of resistin-expressing tumor cells, comprising contacting the cells with the above-mentioned antibody or antigen-binding fragment thereof.

[0120] The tumor cells include, without limitation, any type of tumor cells that express resistin.Preferably, the tumor cells that express resistin may be, but are not limited to, breast cancer, metastatic cancer, uterine cancer, ovarian cancer, prostate cancer, melanoma, lung cancer, liver cancer, glioma, colon cancer, head and neck cancer, bladder cancer, renal cell carcinoma, gastric cancer, pancreatic cancer, and recurrent cancer cells.

[0121] The present invention relates to a method for treating cancer, a cardiometabolic disease, an autoimmune disease or an inflammatory disease comprising the step of administering to an individual a pharma- ceutical effective amount of an antibody or an antigen-binding fragment thereof.

[0122] The method of treatment using the antibody or antigen-binding fragment thereof of the present invention comprises administering said antibody or antigen-binding fragment thereof in a pharmacologic effective amount. It will be apparent to those skilled in the art that the appropriate total daily dose can be determined by the treating physician within the scope of sound medical judgment. It may also be administered in one or more separate doses. However, for purposes of the present invention, it is preferred that the specific therapeutically effective amount for a particular patient will vary depending on a variety of factors, including the type and extent of the response to be achieved, the specific composition, including if other formulations are used, the age, weight, general health, sex and diet of the patient, the time of administration, the route of administration and the duration of treatment, drugs used together with or simultaneously with the specific composition, and similar factors well known in the pharmaceutical arts.

[0123] Subjects to which the compositions of the present invention may be administered include, without limitation, mammals, including humans. The term "administration" in the present invention means introducing the pharmaceutical composition of the present invention into a patient by any suitable method, and the administration route of the composition of the present invention may be via various routes, such as oral or parenteral, as long as it can reach the target tissue. EXAMPLES

[0124] The present invention will be described in more detail below with reference to examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of illustrating the present invention and are not to be construed as limiting the scope of the present invention thereto.

[0125] Example 1: Expression and purification of resistin antigen To express the RETN-C-Fc protein, which is a protein made by fusing a human antibody Fc sequence to the C-terminus of the resistin sequence, and the RETN-flag-His protein, which is a protein made by fusing a flag sequence and a histidine sequence to the C-terminus of the resistin sequence, in animal cells, HEK-293F cells were transfected with RETN-flag-His DNA and cultured for a certain period of time, after which the culture medium was collected. To transfect, DNA was placed in a freestyle 293 expression culture medium, and 200 μg of PEI (polyethylenimine) was added to prepare a polyplex reaction solution. The polyplex reaction solution was left to react at room temperature for 20 minutes, and 1X10 6 The cells were placed in an 80 ml HEK293F cell culture flask and cultured for 7 days at 37°C, 8% CO2, and 85 rpm.

[0126] After 7 days, the culture medium was collected and centrifuged at 5000 rpm for 10 minutes to precipitate and remove the cells and cell debris in the culture medium. To purify and obtain the antigen protein in the resulting supernatant, the supernatant of the RETN-C-Fc antigen DNA transfection culture medium was reacted with a column packed with recombinant protein A agarose resin at 4°C for 16 hours to adsorb the antigen protein to the resin, and then eluted with 0.1M pH 3.3 glycine solution. The eluted protein was neutralized to pH 7-7.4 with 1M Tris-HCl solution, and the solvent was exchanged with DPBS using Maxi GeBAflex-tube (12000-14000 MWCO, D050-100). To purify the RETN-flag-His antigen, the culture supernatant was reacted with a column packed with Ni Sepharose 6 Fast Flow (GE healthcare, 17531803) resin at 4°C for 16 hours to adsorb the antigen protein to the resin, and then eluted with 500 mM imidazole solution. The eluted protein was solvent exchanged with DPBS and concentrated using Maxi GeBAflex-tube (12000-14000 MWCO, D050-100). The purity of the purified protein was confirmed using SDS-PAGE gel (Figure 1).

[0127] Example 2: Primary screening of resistin human antibodies Example 2-1: Biopanning Biopanning was performed to obtain a phage pool that binds to the resistin antigen. The RETN-C-Fc or RETN-flag-His antigen prepared in Example 1 was coated on an immunosorbent tube, followed by blocking. The human antibody library phage was prepared by infecting E. coli with the human scFv library, culturing the tube, and then recovering and concentrating the culture medium. The human antibody library phage was placed in an antigen-coated immunotube for reaction, and the scFv phage bound to the antigen was eluted. The phage obtained in the first round of panning was recovered, reinfected with E. coli for amplification, and then the second and third rounds of biopanning were performed using the RETN-C-Fc or RETN-flag-His antigen. A polyphage pool that binds to the antigen was obtained in each round.

[0128] Example 2-2: Polyphage ELISA Polyphage ELISA was performed to confirm the specific binding of the scFv phage pool obtained in each round to the antigen. 100ng / well of RETN-flag-His antigen and RETN-C-Fc antigen were coated as specific antigens on a 96-well immune plate (NUNC, 439454) and blocked with skim milk. After treating each well with the scFv phage obtained in each round and reacting, the wells were washed with PBS-T and reacted with anti-M13-HRP (Amersham, 27-9421-01) at 1:2000 as a secondary antibody. After washing with PBS-T, 100μl of OPD (sigma, 8787-TAB) solution was treated in each well and reacted with the substrate for 10 minutes. After 10 minutes, each well was treated with 50 μl of 1N H2SO4 to stop the substrate reaction, and then the intensity was measured at 490 nm using a spectrophotometer (Thermo Fisher Scientific, 51119200).

[0129] As a result, it was confirmed that the antigen binding ability of the polyphage pool obtained in each round increased (enriched) as the rounds progressed (Fig. 2a and Fig. 2b).

[0130] Example 2-3: Screening for positive phages (monophage ELISA) Colonies obtained from the third round polyphage pool with high antigen binding ability were inoculated into 1 ml of 2xYTCM (2% glucose, 5 mM MgCl2) medium, placed in a 96-well deep well plate (Bionia, 90030), and cultured in an incubator at 37°C for 16 hours. 100-200 μl of the cultured cell culture liquid was taken so that the OD600 value was 0.1, inoculated into 1 ml of 2xYTCM (2% glucose, 5 mM MgCl2) medium, and cultured in an incubator at 37°C for 2-3 hours. After culture, M1 helper phage was added so that the M value was 1:20, inoculated into 2xYTCMK (5 mM MgCl2, 1 mM IPTG), and reacted at 30°C for 16 hours.

[0131] Resistin antigen was coated at 100ng / well on a 96-well immune plate (NUNC, 439454) and blocked with skim milk. Monoclonal scFv phage cultured for 16 hours was treated in 100μl portions per well and reacted for 2 hours, then washed with PBS-T and reacted with anti-M13-HRP (Amersham, 27-9421-01) at 1:2000 as a secondary antibody. After washing with PBS-T, OPD (Sigma, 8787-TAB) solution was treated in 100μl portions per well and reacted with the substrate for 10 minutes. After 10 minutes, 50μl of 1N H2SO4 was treated in each well to stop the substrate reaction, and the fluorescence was measured at 490nm using a spectrophotometer (Thermo Fisher Scientific, 51119200). A total of 20 antigen-specific clones were obtained (FIGS. 3a and 3b).

[0132] Example 3: Production of primary screening resistin human antibodies Example 3-1: Conversion to IgG type The 20 types of anti-resistin monoclonal phage antibodies selected in Example 2-3 were converted from scFv structure to IgG structure. In order to insert the DNA of each clone into the entire vector, PCR was performed to add a restriction enzyme sequence before and after each heavy chain and light chain. The obtained heavy chain and light chain DNA and the entire vector were treated with a restriction enzyme, and then treated with ligase (T4 DNA ligase, thermofisher scientific, #EL0011) and ligated at 22°C for 10 minutes to insert the heavy chain and light chain sequences into the vector. The prepared vector was transformed into a transformant cell (competent cell, XLI-blue) by heat shock transformation at 42°C, and then spread on an LB ampicillin plate medium and cultured at 37°C for 16 hours or more to obtain colonies. The obtained colonies were inoculated into an LB ampicillin medium and cultured at 37°C for 16 hours. After the incubation, the colony culture was collected and centrifuged at 3000 rpm to obtain the supernatant. DNA was extracted from the supernatant using a DNA prep kit (Nuclogen). The DNA sequence was analyzed to confirm that the cloning was successful.

[0133] Example 3-2: Production of human antibody protein The heavy chain vector and light chain vector DNA obtained by cloning were co-transfected into HEK293F cells at a ratio of 6:4 (light chain, heavy chain). PEI (polyethylenimine) and vector DNA were mixed to prepare a polyplex reaction solution, which was then transfected into cells. The culture medium was harvested on the 7th day after transfection, and the proteins in the supernatant were purified using recombinant protein A agarose resin.

[0134] Example 4: Primary Screening Resistin Human Monoclonal Antibody Characteristics Example 4-1 Analysis of Antigen Receptor Binding Inhibitory Ability Antibody candidates were selected based on their inhibitory effect on the binding of CAP1 to resistin using an in vitro pull-down assay. THP-1 cell lysate was mixed with Fc-fused recombinant resistin protein and each antibody, and then precipitated with Fc beads to measure the bound CAP1 by Western blotting. The binding of resistin to CAP1 and the inhibitory effect of each antibody were compared.

[0135] Specifically, THP-1 (ATCC TIP-202, Homo sapiens, Human) cells were cultured using the cell line culture method provided by ATCC (American Type Culture Collection), the distributor. The cells were cultured in RPMI-1640 medium (pH 7.4) containing 100 units / ml penicillin and 100 μg / ml streptomycin at a temperature of 37°C and in an incubator maintained at a CO2 partial pressure of 5%. THP-1 cells were lysed in lysis buffer (20mM Tris pH 7.5, 150mM NaCl, 1% Triton X-100, 0.25% sodium deoxycholate, 1mM EDTA, 1mM NaF, 1mM Na3VO4, and protease inhibitor cocktail) to extract proteins. The extracted THP-1 protein (500μg) was added with mFc-hResistin (0.5μg) protein and 100ng of antibody and incubated overnight at 4℃. mFc beads (20μl) were added and pulled down at 4℃ for 3 hours, then washed three times with lysis buffer, and SDS-PAGE sample buffer containing β-mercaptoethanol was added, boiled at 100℃ for 5 minutes, and centrifuged to obtain the supernatant. Western blotting was performed to confirm whether the binding of hCAP1 to mFc-hResistin was inhibited by the VS peptide, using hCAP1 antibody and mFc-HRP antibody.

[0136] As a result of analyzing the antigen receptor binding inhibitory ability of the 16 proteins obtained in the first screening, five proteins (1A2, 2E12, 5A2, 3B5, and 4D12) that showed excellent effects were identified (Figure 4).

[0137] Example 4-2: Analysis of antigen affinity To investigate the affinity between the antibody and the resistin antigen, we used the Octet (Forte bio) system, which can investigate ligand-receptor binding in real time using a biosensor. This system is a device that binds the resistin antigen protein to a biosensor, flows the antibody, and optically analyzes the degree of antibody binding to the antigen bound to the sensor, measuring the level of antibody binding to the antigen with high sensitivity at the optical wavelength level. The affinity for the resistin antigen is expressed as the K on (association constants, binding rate) and K dis The equilibrium dissociation constants (KD) for the binding and dissociation reactions are shown.

[0138] As a result, of the five candidate antibodies, 1A2, 2E12, 5A2, 3B5, and 4D12, which showed excellent effects in the antigen receptor binding inhibition assay, four clones except for 2E12 showed antigen affinity, with a KD of 1 nM (Figure 5).

[0139] Example 5: Secondary screening of resistin human antibodies Example 5-1: Biopanning In addition to the primary screening, secondary screening was performed to obtain candidate antibodies with high affinity to the antigen. Using the RETN-C-Fc or RETN-flag-His antigen prepared in Example 1, an immunosorb tube was coated with the antigen and reacted with human antibody library phages in the same manner as in Example 2, and the scFV phages bound to the antigen were eluted. A total of three rounds of biopanning were performed, and a polyphage pool that bound to the antigen in each round was obtained.

[0140] Example 5-2: Analysis of antigen-specific binding ability of scFv phage antibodies The scFv polyphage pool obtained from biopanning was cloned by monophage ELISA to obtain 84 scFv monoclonals. To analyze their antigen-specific binding ability, 100ng / well of resistin antigen and nonspecific antigen were coated on a 96-well immune plate (NUNC, 439454) and reacted with monoclonal scFv phages. After reacting with secondary antibody anti-M13-HRP (Amersham, 27-9421-01), 100μl of OPD (Sigma, 8787-TAB) solution was added to each well and reacted with the substrate for 10 minutes. After stopping the substrate reaction with 1N H2SO4, the intensity was measured at 490nm using a spectrophotometer (Thermo Fisher Scientific, 51119200). As a result, 11 new clones with novel sequences and antigen-specific binding were isolated (FIG. 6).

[0141] Example 6: Tertiary screening of resistin human antibodies Example 6-1: Biopanning In addition to the primary and secondary screenings, a tertiary screening was performed to obtain candidate antibodies with high affinity to the antigen. Using the RETN-C-Fc or RETN-flag-His antigen prepared in Example 1, an immunosorb tube was coated with the antigen and reacted with human antibody library phages in the same manner as in Example 2, and the scFV phages bound to the antigen were eluted. A total of three rounds of biopanning were performed to obtain a polyphage pool that bound to the antigen in each round.

[0142] Example 6-2: Analysis of antigen-specific binding ability of scFv phage antibodies The scFv polyphage pool obtained from biopanning was cloned by monophage ELISA, and 88 scFv monoclonals were isolated. Their antigen-specific binding ability was analyzed by enzyme immunoassay, and 10 novel clones with novel sequences and antigen-specific binding were isolated (Figures 7a and 7b).

[0143] Example 7: Production of Secondary and Tertiary Screening Resistin Human Antibody Example 7-1: Conversion to IgG type A total of 20 monoclonal phage antibodies obtained from the second and third screenings were converted from scFv to IgG structures. As in Example 3, the DNA of each clone was ligated and inserted into a production vector, and then transformed into competent cells (XLI-blue). The transformed cells were cultured in a selective medium, and DNA was extracted therefrom and confirmed by sequence analysis.

[0144] Example 7-2: Production of human antibody protein The heavy and light chain vector DNAs obtained by cloning were co-transfected into HEK293F cells at a ratio of 6:4 (light chain, heavy chain). PEI (polyethylenimine) and vector DNA were mixed to prepare a polyplex reaction solution, which was then transfected into cells. Soytone (BD, USA) was used as an enhancer. The culture medium was harvested on the 7th day after transfection, and the proteins in the supernatant were purified using recombinant protein A agarose resin.

[0145] Example 8: Secondary and tertiary screening properties of resistin human monoclonal antibodies Example 8-1: Analysis of antigen receptor binding inhibition ability Antibody candidates were selected based on their inhibitory effect on the binding of CAP1 to resistin using an in vitro pull-down assay. THP-1 cell lysate was mixed with Fc-fused recombinant resistin protein and each antibody, and then precipitated with Fc beads to measure the bound CAP1 by Western blotting. The binding of resistin to CAP1 and the inhibitory effect of each antibody were compared.

[0146] Specifically, THP-1 (ATCC TIP-202, Homo sapiens, Human) cells were cultured using the cell line culture method provided by ATCC (American Type Culture Collection), the distributor. The cells were cultured in RPMI-1640 medium (pH 7.4) containing 100 units / ml penicillin and 100 μg / ml streptomycin at a temperature of 37°C and in an incubator maintained at a CO2 partial pressure of 5%. THP-1 cells were lysed in lysis buffer (20mM Tris pH 7.5, 150mM NaCl, 1% Triton X-100, 0.25% sodium deoxycholate, 1mM EDTA, 1mM NaF, 1mM Na3VO4, and protease inhibitor cocktail) to extract proteins. The extracted THP-1 protein (500μg) was added with mFc-hResistin (0.5μg) protein and 100ng of antibody and incubated overnight at 4℃. mFc beads (20μl) were added and the cells were pulled down at 4℃ for 3 hours, washed three times with lysis buffer, and then SDS-PAGE sample buffer containing β-mercaptoethanol was added, boiled at 100℃ for 5 minutes, and centrifuged to obtain the supernatant. Western blotting was performed to confirm whether the binding of hCAP1 to mFc-hResistin by the VS peptide was inhibited using hCAP1 antibody and mFc-HRP antibody. As a result, five types (11G01, 27A04, 32B05, 32E06, and 32G09) that showed excellent effects were identified (Figure 8).

[0147] Example 8-2: Analysis of antigen-specific binding ability Enzyme-linked immunosorbent assay (ELISA) was performed to investigate the specific binding of the screening clones to human resistin protein and to confirm the presence or absence of non-specific binding to other antigen proteins. The RETN-flag-His antigen and non-specific antigen prepared in Example 1 were diluted to 10 nM in DPBS and placed in a 96-well immune plate (NUNC, 439454) at 100 μl per well, and then coated at 4°C for 16 hours. Then, the plate was blocked with 4% skim milk in PBS at 37°C for 1 hour. The antibody proteins were diluted with 1% skim milk in PBS to 1, 10, and 100 nM, respectively, and added in 100 μl per well and reacted at 37° C. for 2 hours. After washing with PBS-T, anti-human Fc-HRP (Pierce® Peroxidase Conjugated Goat Anti-Human IgG FC (thermo fisher scientific, 31413) was diluted 1:10000 as a secondary antibody and reacted at 37° C. for 1 hour. After washing with PBS-T, 100 μl of TMB (sigma, T0440) solution was added to each well and reacted with the substrate for 10 minutes. After 10 minutes, 50 μl of 1N H2SO4 was added to each well to stop the substrate reaction, and the fluorescence was measured at 490 nm using a spectrophotometer (thermo fisher scientific, 51119200).

[0148] As a result, all five antibodies, 11G01, 27A04, 32B05, 32E06, and 32G09, which showed excellent effects in the antigen receptor binding inhibition assay, showed high specific binding to the RETN-flag-His antigen protein (Figure 9a).In addition, all five antibodies that showed excellent effects in the antigen receptor binding inhibition assay against five nonspecific antigens did not bind nonspecifically (Figure 9b).

[0149] Example 8-3: Analysis of antigen affinity To investigate the affinity between the antibody and resistin antigen, a ligand-receptor assay was performed using the Octet (Forte bio) system biosensor. As a result, of the five candidate antibodies that showed efficacy in the antigen receptor binding inhibitory ability assay, four showed antigen affinity at a KD of 1 nM level (FIG. 10).

[0150] Example 8-4: Anti-resistin primary antibody screening

[0151] From the sequence analysis results of 40 monoclonal antibodies obtained in the first to third screenings, the CDR regions of VH and VL of each clone were investigated, and the similarity with the germ line antibody group was analyzed using the Ig BLAST program on the NCBI webpage http: / / www.ncbi.nlm.nih.gov / igblast / . The results are shown in Table 7 below.

[0152] [Table 7] TIFF2024542149000015.tif134170

[0153] Example 9: Optimization of antibodies against resistin antibody RETN-5A2 clone For antibody optimization, the heavy chain of the RETN-5A2 clone was immobilized and diluted with 1x10 6 A light chain (LC) pool with a diversity of 1x10 was used to create a light chain shuffling library with a combination of a new light chain and an existing heavy chain. The light chain site of the RETN-5A2 gene was removed by restriction enzyme cleavage, and the LC shuffling library was then shuffled with 1x10 6 The diverse light chain pool was ligated to RETN-5A2 DNA that had been digested with the same restriction enzyme to remove the light chain. The cloned DNA was transformed into competent cells (XLI-blue), and the cells were then collected to generate a library (Figure 11).

[0154] Example 10: Screening for resistin human antibodies Example 10-1: Biopanning Biopanning was performed to obtain an optimized phage pool using the 5A2 antibody that binds to the resistin antigen as the parent antibody. The RETN-C-Fc or RETN-flag-His antigen prepared in Example 1 was coated on an immunosorbent tube, followed by blocking. The 5A2 antibody optimized library phage was placed in the antigen-coated immunotube and reacted, after which the scFv phage bound to the antigen was eluted. The obtained phage was collected and amplified by infecting Escherichia coli again.

[0155] Example 10-2: Screening of positive phages and obtaining monoclonal antibody sequences Phage ELISA was performed to obtain a specific binding scFv pool for the antigen from the obtained scFv phage pool. RETN-flag-His antigen was coated at 100ng / well on a 96-well immune plate (NUNC, 439454) and blocked with skim milk. After treating each well with the scFv phage obtained in each round and reacting, the wells were washed with PBS-T and reacted with anti-M13-HRP (Amersham, 27-9421-01) at 1:2000 as a secondary antibody. After washing with PBS-T, 100μl of OPD (sigma, 8787-TAB) solution was treated in each well and reacted with the substrate for 10 minutes. After 10 minutes, each well was treated with 50 μl of 1N H2SO4 to stop the substrate reaction, and the activity was measured at 490 nm using a spectrophotometer (Thermo Fisher Scientific, 51119200). As a result, it was confirmed that the antigen binding ability of the phage pool was somewhat enriched after biopanning (Figure 12).

[0156] Colonies obtained from the first round polyphage pool, whose binding ability to antigen was confirmed, were inoculated into 1 ml of 2xYTCM (2% glucose, 5 mM MgCl2) medium, placed in a 96-well deep well plate (Bionia, 90030), and cultured in an incubator at 37°C for 16 hours. The cultured cell culture was taken from 10 to 200 so that the OD600 value was 0.1, inoculated into 1 ml of 2xYTCM (2% glucose, 5 mM MgCl2) medium, and cultured in an incubator at 37°C for 2 to 3 hours. After culture, M1 helper phage was added so that the M value was 1:20, inoculated into 2xYTCMK (5 mM MgCl2, 1 mM IPTG), and reacted at 30°C for 16 hours.

[0157] Resistin antigen was coated at 100ng / well on a 96-well immune plate (NUNC, 439454) and blocked with skim milk. Monoclonal scFv phage cultured for 16 hours was treated in 100μl portions per well and reacted for 2 hours, then washed with PBS-T and reacted with anti-M13-HRP (Amersham, 27-9421-01) at 1:2000 as a secondary antibody. After washing with PBS-T, OPD (Sigma, 8787-TAB) solution was treated in 100μl portions per well and reacted with the substrate for 10 minutes. After 10 minutes, 50μl of 1N H2SO4 was treated in each well to stop the substrate reaction, and the fluorescence was measured at 490nm using a spectrophotometer (Thermo Fisher Scientific, 51119200).

[0158] As a result, a total of 36 antigen-specific clones were obtained, and the sequences of the obtained 36 clones were analyzed to obtain 18 clones with unique sequences different from existing sequences (Table 8).

[0159] [Table 8]

[0160] Example 11: Production of resistin human antibody Example 11-1: Conversion to IgG type The 18 selected anti-resistin monoclonal phage antibodies were converted from scFv structure to IgG structure. To insert the DNA of each clone into the entire vector, PCR was performed to add a restriction enzyme sequence before and after each heavy chain and light chain. The obtained heavy chain and light chain DNA and the entire vector were treated with restriction enzymes, then treated with ligase (T4 DNA ligase, Thermofisher Scientific, #EL0011) and ligated at room temperature for 10 minutes to insert the heavy chain and light chain sequences into the vector. The prepared vector was transformed into competent cells (XLI-blue) by heat shock at 42°C, spread on LB ampicillin plate medium, and cultured at 37°C for 16 hours or more to obtain colonies. The obtained colonies were inoculated into LB ampicillin medium and cultured at 37°C for 16 hours. After the culture was completed, the colony culture liquid was collected and centrifuged at 3000 rpm to obtain the supernatant. DNA was extracted from the supernatant using a DNA prep kit (Nuclogen).

[0161] Example 11-2: Production of human antibody protein The heavy chain vector and light chain vector DNA obtained by cloning were co-transfected into HEK293F cells at a ratio of 6:4 (light chain, heavy chain). PEI (polyethylenimine) and vector DNA were mixed to prepare a polyplex reaction solution, which was then transfected into cells. The culture medium was collected on the 7th day after transfection, and the protein in the supernatant was purified with recombinant protein A agarose resin. The concentration of the purified protein was quantified by measuring the absorbance at 280 nm using nano-drop, and the productivity of each clone was evaluated based on this (Table 9). As a result, the productivity was improved by an average of 92% compared to the parent antibody 5A2 clone (Figure 13).

[0162] [Table 9]

[0163] In addition, protein expression was evaluated by injecting reduced and non-reduced proteins into SDS-PAGE to analyze the band pattern, thereby analyzing the purity and size of the produced protein.

[0164] As a result, all 18 screened antibodies showed a size of 150 kDa under non-reducing conditions, and under reducing conditions, proteins of two predicted sizes were detected: a heavy chain of ~50 kDa and a light chain of ~25 kDa (Figure 14).

[0165] Example 12: Characterization of resistin human monoclonal antibodies Example 12-1: Antigen-specific and non-specific binding (including human intact binding ability) Enzyme-linked immunosorbent assay (ELISA) was performed to confirm the specific binding ability of the resistin-optimized antibody protein to the resistin antigen. The RETN-flag-His antigen and nonspecific antigen prepared in Example 1 were diluted to 10 nM in DPBS and placed in a 96-well immune plate (NUNC, 439454) at 100 μl per well, and then coated at 4° C. for 16 hours. Then, the plate was blocked with 4% skim milk in PBS at 37° C. for 1 hour. The antibody proteins were diluted with 1% skim milk in PBS to 1, 10, and 100 nM, respectively, and added in 100 μl per well and reacted at 37° C. for 2 hours. After washing with PBS-T, anti-human Fc-HRP (Pierce® Peroxidase Conjugated Goat Anti-Human IgG FC (thermo fisher scientific, 31413) was diluted 1:10000 as a secondary antibody and reacted at 37° C. for 1 hour. After washing with PBS-T, 100 μl of TMB (sigma, T0440) solution was added to each well and reacted with the substrate for 10 minutes. After 10 minutes, 50 μl of 1N H2SO4 was added to each well to stop the substrate reaction, and the fluorescence was measured at 490 nm using a spectrophotometer (thermo fisher scientific, 51119200).

[0166] As a result, most of the clones, except for some clones (LS_1F09, LS_1G11), showed antigen-binding reactions similar to those of 5A2 (Fig. 15a). In addition, none of the 18 optimized antibodies bound nonspecifically to the five nonspecific antigens (Fig. 15b).

[0167] The antigen prepared in Example 1 had a human antibody Fc sequence or histidine sequence artificially added to the C-terminus of the antigen to facilitate purification and analysis. To confirm that the effect on the antigen in its natural state was the same as that of the antibody confirmed with the artificial antigen, an enzyme-linked immunosorbent assay (ELISA) was performed using a recombinant human antigen (Recombinant Human Resistin, Peprotech, #450-19) with the same natural structure. The antibody samples were evaluated using 13 optimized antibodies, excluding LS_1E09, LS_2B10, LS_2B12, LS_2E11, and LS_2D09, which are five types with significantly lower production and resistin antigen binding ability than the parent antibody 5A2 clone. Recombinant human antigen (Peprotech, #450-19) was diluted in DPBS to a concentration of 10 nM and placed in 100 μl per well on a 96-well immune plate (NUNC, 439454), and then coated at 4° C. for 16 hours. Then, the sections were blocked with 4% skim milk diluted in PBS at 37° C. for 1 hour. The antibody proteins were diluted with 1% skim milk in PBS to 1, 10, and 100 nM, respectively, and added in 100 μl per well and reacted at 37° C. for 2 hours. After washing with PBS-T, anti-human Fc-HRP (Pierce® Peroxidase Conjugated Goat Anti-Human IgG FC (thermo fisher scientific, 31413) was diluted 1:10000 as a secondary antibody and reacted at 37° C. for 1 hour. After washing with PBS-T, 100 μl of TMB (sigma, T0440) solution was added to each well and reacted with the substrate for 10 minutes. After 10 minutes, 50 μl of 1N H2SO4 was added to each well to stop the substrate reaction, and the fluorescence was measured at 490 nm using a spectrophotometer (thermo fisher scientific, 51119200).

[0168] As a result, all clones, including the parent antibody 5A2, showed binding activity to intact form resistin that was very similar to the binding activity of existing his-tag resistin, which is expected to enable prediction of the efficacy of candidate clones against natural antigens (Figure 15c).

[0169] Example 12-2: Interspecies cross-linking reactions against mouse antigens Enzyme-linked immunosorbent assay (ELISA) was performed to examine the interspecies cross-binding reaction of the eight optimized antibodies, excluding LS_1E09, LS_2B10, LS_2B12, LS_2E11, and LS_2D09, which are five antibodies with significantly lower production and binding ability to the resistin antigen than the parent antibody 5A2 clone, against mouse resistin antigen. The mouse antigen used was murine resistin (#450-28) from Peprotech. The mouse antigen was diluted to 10 nM in DPBS and placed in 100 μl per well of a 96-well immune plate (NUNC, 439454), and coated at 4°C for 16 hours. The plate was then blocked with 4% skim milk diluted in PBS at 37°C for 1 hour. The antibody proteins were diluted with 1% skim milk in PBS to 1, 10, and 100 nM, respectively, and added in 100 μl per well and reacted at 37° C. for 2 hours. After washing with PBS-T, anti-human Fc-HRP (Pierce® Peroxidase Conjugated Goat Anti-Human IgG FC (thermo fisher scientific, 31413) was diluted 1:10000 as a secondary antibody and reacted at 37° C. for 1 hour. After washing with PBS-T, 100 μl of TMB (sigma, T0440) solution was added to each well and reacted with the substrate for 10 minutes. After 10 minutes, 50 μl of 1N H2SO4 was added to each well to stop the substrate reaction, and the fluorescence was measured at 490 nm using a spectrophotometer (thermo fisher scientific, 51119200).

[0170] As a result, in contrast to their binding ability to the RETN-flag-His antigen, the parent antibody 5A2 clone and the eight optimized antibodies did not bind to the mouse antigen, confirming the absence of interspecies cross-reaction with mouse resistin (Figure 16).

[0171] Example 12-3 Analysis of antigen receptor binding inhibition ability using antigen receptor competitive enzyme immunoassay (resistin-CAP1 competitive ELISA) To evaluate the antibody's ability to bind to resistin and inhibit antigen receptor binding, an antigen receptor competitive enzyme-linked immunosorbent assay (ELISA) was performed. A 96-well plate was coated with antigen protein, treated with antibody at different concentrations, and then the receptor was treated to detect the receptor protein bound to the antigen. A schematic diagram of the analysis method is shown in Figure 17a. The coated antigen protein used was the RETN-C-Fc protein prepared in Example 1, and the receptor protein used was purchased CAP1-His (LSbio, LS-G13682-100) with histidine binding.

[0172] RETN-C-Fc protein was diluted to 100 nM in DPBS and added to a 96-well immune plate (NUNC, 439454) at 100 μl per well and coated at room temperature for 16 hours. Then, it was blocked with 4% skim milk diluted in PBS at 37°C for 1 hour. Antibody protein was serially diluted 5-fold from the highest concentration of 500 nM to 0.0064 nM and added to 100 μl per well and reacted at room temperature for 2 hours. Then, after washing with PBS-T, CAP1-His was diluted to 100 nM in 1% skim milk diluted in PBS and added to 100 μl per well and reacted at room temperature for 2 hours. After washing with PBS-T, anti-Histidine-biotin (Invitrogen, MA1-21315-BTIN) was diluted 1:2000 in 1% skim milk and added at 100 μl per well, and reacted at room temperature for 1 hour. Streptavidin-HRP (Thermo Fisher Scientific, 21140) was diluted 1:1000 and reacted for 1 hour. After washing with PBS-T, 100 μl of TMB (Sigma, T0440) solution was added to each well and reacted with the substrate for 10 minutes. After 10 minutes, 50 μl of 1N H2SO4 was added to each well to stop the substrate reaction, and the fluorescence was measured at 490 nm using a spectrophotometer (Thermo Fisher Scientific, 51119200).

[0173] As a result, in Examples 11 and 12, among the clones with productivity and antigen binding ability superior to the parent antibody 5A2, seven top clones (5A2_LS_1F11, 5A2_LS_2B02, 5A2_LS_2D07, 5A2_LS_2F11, 5A2_LS_2G03, 5A2_LS_2E10 and 5A2_LS_2H10) with superior antigen receptor binding inhibitory ability to 5A2 were selected (Figure 17b).

[0174] Example 12-4: Analysis of antigen receptor binding inhibition ability Antibody candidates were selected based on their inhibitory effect on the binding of CAP1 to resistin using an in vitro pull-down assay. THP-1 cell lysate was mixed with Fc-fused recombinant resistin protein and each antibody, and then precipitated with Fc beads to measure the bound CAP1 by Western blotting. The binding of resistin to CAP1 and the inhibitory effect of each antibody were compared.

[0175] Specifically, THP-1 (ATCC TIP-202, Homo sapiens, Human) cells were cultured using the cell line culture method provided by ATCC (American Type Culture Collection), the distributor. The cells were cultured in RPMI-1640 medium (pH 7.4) containing 100 units / ml penicillin and 100 μg / ml streptomycin at a temperature of 37°C and in an incubator maintained at a CO2 partial pressure of 5%. THP-1 cells were lysed in lysis buffer (20mM Tris pH 7.5, 150mM NaCl, 1% Triton X-100, 0.25% sodium deoxycholate, 1mM EDTA, 1mM NaF, 1mM Na3VO4, and protease inhibitor cocktail) to extract proteins. Extracted THP-1 protein (500μg) was added with mFc-hResistin (0.5μg) protein and 100ng of antibody and incubated overnight at 4℃. mFc beads (20μl) were added and pulled down at 4℃ for 3 hours, then washed three times with lysis buffer, added with SDS-PAGE sample buffer containing β-mercaptoethanol, boiled at 100℃ for 5 minutes, and centrifuged to obtain a supernatant. Western blotting was performed to confirm whether the binding of hCAP1 to mFc-hResistin was inhibited by the VS peptide, using hCAP1 antibody and mFc-HRP antibody. As a result, an antibody was identified that showed a superior effect to the parent antibody 5A2 (FIG. 18).

[0176] Example 12-5: Affinity investigation between antibody and resistin antigen using Octet (Forte bio) system To investigate the affinity between the antibody and the resistin antigen, we used the Octet (Forte bio) system, which can investigate ligand-receptor binding in real time using a biosensor. This system is a device that binds the resistin antigen protein to a biosensor, flows the antibody, and optically analyzes the degree of antibody binding to the antigen bound to the sensor, measuring the level of antibody binding to the antigen with high sensitivity at the optical wavelength level. The affinity for the resistin antigen is expressed as the K on (association constants, binding rate) and K dis The equilibrium dissociation constants (KD) for the binding and dissociation reactions are shown.

[0177] As a result, the seven antibodies that showed superior effects to the parent antibody in the antigen receptor competitive enzyme immunoassay showed antigen affinity of KD 1 nM or less, which is equal to or higher than that of the parent antibody 5A2 (Figure 19).

[0178] Example 13: Analysis of the anti-cancer effect of resistin antibody Example 13-1: NF-κB activation by resistin To confirm the effect of the antibody on NF-κB activity, NF-κB was activated in MB231 cells with resistin, and NF-κB activity when 5A2 and IgG were added was measured by measuring p65 phosphorylation (Figure 20).

[0179] Specifically, the MDA-MB-231 (ATCC HTB-26, Homo sapiens, Human) 293F cell line was cultured in a DMEM medium containing 100 units / ml penicillin and 100 μg / ml streptomycin at pH 7.4 in an incubator at 37°C and 5% CO2 partial pressure, using the cell line culture method of the distributor, ATCC (American Type Culture Collection). 5MB-231 cells were seeded in four 6-well plates and treated with 100 ng / ml anti-resistin 5A2 (Y-BIOLOGICS / ANRT) in 1% FBS-containing DMEM (Invitrogen Life Technologies) medium for 6 h, followed by sequential treatment with 50 ng / ml recombinant human resistin (Y-BIOLOGICS / ANRT, Korea) for 10, 30, and 60 min.

[0180] For Western blotting analysis, equal amounts of cell lysates were harvested and dissolved in lysis buffer containing protease inhibitors (Roche, Cat. 11836153001). Total protein (10–30 μg) was immunoblotted with specific primary antibodies; Phospho-Src (Tyr416) ​​(Cell signaling Technology, #6943), p-p65 (Ser276) (Cell signaling Technology, #3037), total p65 (Santa Cruz Biotechnology, sc-372), p-CREB (Ser133) (Santa Cruz Biotechnology, sc-101663), total CREB (Cell signaling technology, #9197) and α-Tubulin (Calbiochem, Cat. CP06). Anti-mouse IgG HRP and anti-rabbit IgG HRP were purchased from Promega as secondary antibodies, and detection was performed with ECL and ECL-PLUS (Amersham).

[0181] Example 13-2: Analysis of cancer cell migration in vitro To confirm the effect of antibodies on resistin-induced cancer cell migration, a cell migration experiment was performed using MB231 breast cancer cell line treated with 5A2 antibody and IgG.

[0182] 5x10 5MDA-MB-231 breast cancer cells were cultured in 6-well plates. When the cells reached 90% density, they were starved for 24 hours using RPMI1640 medium supplemented with 1% serum. Then, a scratch was induced using a 200p tip, and 100ng / ml recombinant resistin, 100ng / ml human normal IgG, and 100ng / ml 5A2 antibody were added. After 6 hours, the migrated cells were observed using a Leica microscope (DMI3000 B) and quantified using Image J software based on the area of ​​cell migration.

[0183] As a result, 100ng / ml resistin increased the migration of MDA-MB-231 breast cancer cells by approximately 137%. Human normal IgG, used as a negative control, induced breast cancer cell migration at a similar level to the resistin-only treatment group, but when treated with the anti-resistin antibody 5A2, cell migration was inhibited by 55% compared to the resistin-only treatment group, and by 76% compared to the vehicle group (Figure 22).

[0184] Example 13-3: Metastasis of cancer cells in vivo To measure pharmacokinetics, a pharmacokinetic experiment was performed in which mice were administered the 5A2 antibody and a hIgG control group (FIG. 21).

[0185] To confirm the in vivo metastasis suppression ability of 5A2 antibody against breast cancer cells, we first induced hyper-resistinemia in NOD / SCID mice using adenovirus. We confirmed through luminescence imaging and tissue extraction that hyper-resistinemia promotes metastasis of breast cancer cells to the liver and lungs. 7 Adv.GFP and Adv.hResistin were intraperitoneally injected (IP) into NOD / SCID mice. One week later, 6x10 MDA-MB-231 cells overexpressing luciferase were transfected into the cells.5 The tumors were then intravenously injected (IV) with 10 mg / kg human normal IgG and 10 mg / kg 5A2 antibody, which were then administered continuously three times a week. At the fourth week, luminescence images were obtained for each experimental group by administering 150 mg / kg Luciferin. Images were captured using a KODAK FX-PRO device.

[0186] Administration of 10 mg / kg 5A2 antibody for 4 weeks (3 times a week) confirmed a significant reduction in metastasis to the relevant organ. In addition, when the tissue was excised and the number of metastatic colons visible to the naked eye was compared (indicated by arrows in Figure 23), it was found that the number of metastatic colons was significantly reduced in the 5A2 antibody administration group, similar to the results of the luminescence images (Figure 23).

[0187] Example 14: Analysis of the effect of resistin antibody on NASH (non-alcoholic steatohepatitis) Example 14-1: Confirmation of the effect of resistin antibody in improving high-fat diet-induced NASH To determine whether the antibody was effective in improving high-fat diet-induced NASH, fatty liver was induced with a high-fat diet for two months, followed by a high-fat diet for one month, and 5A2 was administered intravenously (IV) (Figure 24).

[0188] Mouse liver tissue was fixed in 4% PFA for 5 days, then cut into paraffin blocks and stained with H&E. The results were measured using the Nonalcoholic Fatty Liver Disease Activity Score (NAS). The NAS score was significantly reduced in the 5A2 antibody administration group (Figure 25).

[0189] Mouse liver tissue was prepared as an OCT block and stained with Oil-Red-O. As a result, it was confirmed that neutral triglycerides and lipids were significantly decreased in the 5A2 antibody administration group (FIG. 26). Example 14-2: Confirmation of the insulin sensitivity improving effect of resistin antibody

[0190] Four weeks after 5A2 administration, an insulin resistance test was performed. Mice were kept fasting for 12 hours before the test, and water was provided. Before insulin administration, the tips of the mouse tails were cut, and fasting blood glucose levels were measured using a Roche AccuCheck blood glucose meter. Then, 0.75 IU of insulin was administered intraperitoneally (IP), and blood glucose levels were measured 15, 30, 60, and 120 minutes later.

[0191] The results showed that the 5A2 antibody administration group had greater insulin sensitivity. In particular, the fasting blood glucose level reduction rate in the 5A2 antibody administration group 30 minutes after insulin administration was 56%, which was more than 20% lower than the control group (FIG. 27).

[0192] Example 14-3: Confirmation of the fasting glucose lowering effect of resistin antibody Fasting blood glucose tests were performed 4 weeks after administration of 5A2. The mice were kept fasting for 12 hours and were provided with water. Blood for blood glucose measurements was obtained by cutting the tip of the mouse's tail with scissors and using a Roche AccuTec blood glucose meter.

[0193] As a result, it was found that fasting blood glucose level in humanized resistin mice overexpressing human resistin was 105.2 mg / dL, which was even lower than that of the control group (125.5 mg / dL) (Figure 28).

[0194] Example 14-4: Confirmation of LDL cholesterol lowering effect of resistin antibody Blood was collected from mice and separated into serum using a capillary blood collection tube. The precipitation buffer provided in the cholesterol assay kit (ab65390) was mixed with an equal amount of serum, and then spun down at 13,000 rpm to separate the supernatant (high-density lipoprotein) and pellet (low-density lipoprotein). The pellet was dissolved in PBS to obtain LDL. Two independent experiments showed that LDL was significantly reduced in the 5A2 antibody administration group compared to the control group (Figure 29).

[0195] Example 14-5: Confirmation of the effect of resistin antibody in reducing triglyceride accumulation 50mg of mouse liver was washed several times with cold PBS, and then homogenized in 1ml of 5% NP-40 / ddH20. It was then heated to 100℃ to dissolve triglycerides. Triglycerides were measured using a triglyceride assay kit (ab65336), and the 5A2 antibody administration group showed a 30% or greater reduction in triglycerides compared to the control group (Figure 30).

[0196] Example 15: Analysis of the effect of resistin antibody on IBD (inflammatory bowel disease) To confirm whether the antibody was effective in improving acute intestinal disease, dextran sodium sulphate (DSS) was mixed at a concentration of 5% in drinking water and provided to the mice for 5 days to induce intestinal disease, and saline, Remsima (1 mg / kg), and RETN-5A2_LS_2F11 antibody (10 mg / kg) were administered intravenously (IV) on days 1 to 3 (Figure 31).

[0197] The body weight of the mice was measured every day from the start of DSS administration, and weight loss began from day 3. Both Remsima and RETN-5A2_LS_2F11 caused less weight loss than the saline group, and RETN-5A2_LS_2F11 was about 3.6% more effective than Remsima (Figure 32).

[0198] Disease Activity Score (DAI) is the sum of scores from 0 to 4 calculated by observing the amount of weight loss (%), stool condition, and bloody stool. DAI was measured daily from the start of DSS administration, and began to increase from the third day. Both Remsima and RETN-5A2_LS_2F11 showed a smaller increase in DAI compared to the saline group, with RETN-5A2_LS_2F11 being approximately 1.4 more effective than Remsima (Figure 33).

[0199] The length of the mouse colon was measured from the cecum to the anus. In the normal group, the length of the intestine was 7.1 cm, and it was reduced to 4.9 cm by DSS. The reduction in the length of the mouse intestine was smaller in both Remsima and RETN-5A2_LS_2F11 compared to the saline group, and the protective effect of the intestine length was increased by about 0.5 cm more in RETN-5A2_LS_2F11 than in Remsima (Figure 34).

[0200] Mouse colon tissue was fixed in 4% PFA for 5 days, then paraffin-blocked and stained with H&E, and the results were measured using histological activity scores. Both Remsima and RETN-5A2_LS_2F11 showed a smaller increase in histological activity score compared to the saline group, and RETN-5A2_LS_2F11 was about 0.8 more effective than Remsima (Figure 35). [Industrial Applicability]

[0201] The novel antibody or antigen-binding fragment thereof that binds to resistin of the present invention can bind to resistin and inhibit its activity by blocking resistin / CAP1 binding, and is therefore useful for developing treatments for various resistin-associated diseases.

[0202] Although the specific parts of the present invention have been described in detail above, it is clear to those skilled in the art that such specific techniques are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:1, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:2, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:3; and An antibody or antigen-binding fragment thereof that specifically binds to resistin, comprising a light chain variable region including CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 to 11, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 to 19, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 to 27.

2. The light chain variable region comprises: a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:4, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:12, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:20; a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:13, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:21; a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:6, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:14, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:22; a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:7, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:23; a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:8, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:16, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:24; a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:9, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:17, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:25; a light chain variable region comprising a CDR1 comprising the amino acid sequence represented by SEQ ID NO: 10, a CDR2 comprising the amino acid sequence represented by SEQ ID NO: 18, and a CDR3 comprising the amino acid sequence represented by SEQ ID NO: 26; or An antibody or antigen-binding fragment thereof that specifically binds to resistin according to claim 1, characterized in that it comprises a light chain variable region comprising CDR1 having the amino acid sequence shown in SEQ ID NO: 11, CDR2 having the amino acid sequence shown in SEQ ID NO: 19, and CDR3 having the amino acid sequence shown in SEQ ID NO:

27.

3. The antibody or antigen-binding fragment thereof that specifically binds to resistin according to claim 1, wherein the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:

28.

4. The antibody or antigen-binding fragment thereof that specifically binds to resistin described in claim 2, characterized in that the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 34, 36, 38, 40, 42, 44 and 46.

5. A heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:28; and An antibody or antigen-binding fragment thereof that specifically binds to resistin as described in claim 1, characterized in that it comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 34, 36, 38, 40, 42, 44 and 46.

6. A nucleic acid encoding the heavy chain variable region of the antibody or antigen-binding fragment thereof according to claim 1.

7. The nucleic acid according to claim 6, characterized in that the nucleic acid comprises the base sequence shown in SEQ ID NO:

30.

8. A nucleic acid encoding the light chain variable region of the antibody or antigen-binding fragment thereof according to claim 1.

9. The nucleic acid according to claim 8, characterized in that the nucleic acid comprises a base sequence selected from the group consisting of SEQ ID NOs: 48, 50, 52, 54, 56, 58, 60 and 62.

10. An expression vector comprising a nucleic acid encoding a heavy chain variable region of the antibody or antigen-binding fragment thereof described in claim 6, and a nucleic acid encoding a light chain variable region of the antibody or antigen-binding fragment thereof described in claim 8.

11. A cell transformed with the expression vector according to claim 10.

12. The cell according to claim 11, characterized in that it is selected from the group consisting of animal cells, plant cells, yeast, Escherichia coli and insect cells.

13. A method for producing an antibody or antigen-binding fragment thereof that specifically binds to resistin, comprising the steps of: (a) culturing the cell of claim 11; and (b) recovering the antibody or antigen-binding fragment thereof from the cultured cells.

14. An antibody-drug conjugate (ADC) in which a drug is bound to the antibody or antigen-binding fragment thereof described in claim 1.

15. The antibody-drug conjugate of claim 14, wherein the antibody or antigen-binding fragment thereof is conjugated to the drug via a linker.

16. The antibody-drug conjugate of claim 15, wherein the linker is a cleavable linker or a non-cleavable linker.

17. 15. The antibody-drug conjugate of claim 14, wherein the drug is a chemotherapeutic agent, a toxin, a microRNA (miRNA), an siRNA, an shRNA or a radioisotope.

18. A bispecific or multi-specific antibody comprising the antibody or antigen-binding fragment thereof described in claim 1.

19. A chimeric antigen receptor (CAR) comprising the antibody or antigen-binding fragment thereof described in claim 1.

20. 20. An immune cell comprising the chimeric antigen receptor of claim 19.

21. The immune cell according to claim 20, characterized in that the immune cell is a T cell or a NK cell.

22. A pharmaceutical composition for preventing or treating a disease treatable by inhibiting resistin activity, comprising an antibody or antigen-binding fragment thereof described in claim 1, an antibody-drug conjugate described in claim 14, a bispecific or multispecific antibody described in claim 18, or a chimeric antigen receptor described in claim 19.

23. The pharmaceutical composition according to claim 22, characterized in that the activity of resistin is inhibited by blocking resistin / CAP1 binding with a resistin antibody.

24. The pharmaceutical composition according to claim 22, wherein the disease treatable by inhibiting resistin activity is cancer, a cardiometabolic disease, an autoimmune disease or an inflammatory disease.

25. 25. The pharmaceutical composition according to claim 24, wherein the cancer is selected from the group consisting of breast cancer, metastatic cancer, uterine cancer, ovarian cancer, prostate cancer, melanoma, lung cancer, liver cancer, glioma, colorectal cancer, head and neck cancer, bladder cancer, renal cell carcinoma, gastric cancer, pancreatic cancer and recurrent cancer.

26. 25. The pharmaceutical composition according to claim 24, wherein the cardiometabolic disease is selected from the group consisting of obesity, hyperlipidemia, hypertension, arteriosclerosis, hyperinsulinemia, insulin-resistant diabetes, type 2 diabetes, liver disease, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

27. 25. The pharmaceutical composition according to claim 24, wherein the autoimmune disease is selected from the group consisting of chronic heart disease, rheumatoid arthritis, generalized erythematous cyst, digestive system diabetes, atopic dermatitis, autoimmune encephalomyelitis, asthma and Crohn's disease.

28. 25. The pharmaceutical composition according to claim 24, characterized in that the inflammatory disease is selected from the group consisting of inflammatory skin diseases including asthma, eczema, psoriasis, acne, allergies, rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, atopic rhinitis, allergic dermatitis, chronic sinusitis or seborrheic dermatitis; inflammatory bowel diseases including Crohn's disease or ulcerative colitis, acute or chronic inflammatory diseases including ankylosing spondylitis, sepsis, septic shock, vasculitis and bursitis.

Citation Information

Patent Citations

  • Anti-resistin immune neutralizing antibody and application in treatment of breast cancer

    CN108484768A

  • Resistin antagonists and their use

    JP2010508027A

  • Resistin antagonists and their use

    JP2010539937A

  • Antibodies to human resistin

    US20160130341A1

  • Pharmaceutical composition for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation

    WO2021177518A1